Semaxinib

Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM[1].

Product Specifications

CAS Number

[204005-46-9]

Product Name Alternative

SU5416

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SU5416.html

Purity

99.96

Solubility

DMF : 50 mg/mL (ultrasonic) |DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=CC=C/21)C2=C/C3=C(C)C=C(C)N3

Molecular Formula

C15H14N2O

Molecular Weight

238.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Fong TA, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59 (1), 99-106.|[2]Vajkoczy P, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia, 1999, 1 (1), 31-41.|[3]Happé CM, et al. Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310 (11) :L1088-97.|[4]Izquierdo-Garcia JL, et al. Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension. Front Cardiovasc Med. 2018 Aug 15;5:110.